Drug Profile
Research programme: eye disorder therapeutics - EyePoint Pharmaceuticals/Undisclosed company
Latest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Undisclosed
- Developer EyePoint Pharmaceuticals; Undisclosed Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for research development in Eye-disorders in USA (Ophthalmic)
- 28 Mar 2018 pSivida is now called EyePoint Pharmaceuticals
- 12 May 2015 pSivida and an undisclosed leading global pharmaceutical company agree to evaluate Durasert™ drug delivery technology for eye disorder therapeutics